Aktuellt
SENASTE
Redeye provides a brief comment on Cereno’s Q1 2022 report. Cereno plans to communicate top-line data from its phase II trial with CS1 in PAH in late 2022, which we view as the primary catalyst for the share in the coming 12 months. Should the company deliver positive top-line data, we judge Cereno’s share could appreciate substantially.
LÄS MER
